REFERENCES
American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 20(suppl 1):S5-S13, 1997
DeFronzo RA: The triumvirate: B-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 37:667-687, 1988
Henry RR: Thiazolidinediones. Endocrin Metabol Clin North Am 26:553-573, 1997
Spencer CM, Markham A: Troglitazone. Drugs 54:89-101, 1997
Inzucchi ES, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N Engl J Med 338:867-872, 1998
Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998
Parke-Davis: Data on file. Morris Plains, New Jersey.
Wise J: Diabetes drug withdrawn after reports of hepatic events. BMJ 315(7122):1564, 1997
Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36-38, 1998
Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 129:38-41, 1998
Vella A, de Groen PC, Dinneen BF: Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 129:1080, 1998 (letter)
Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917, 1998 (letter)
Misbin RI: Review of liver toxicity of troglitazone. Meeting of the Food and Drug Adminstration Cardiorenal Advisory Committee, January 21, 1998. Bethesda, Maryland
Parke-Davis: Prescribing information for Rezulin. Morris Plains, New Jersey. July 1998
Zimmerman HJ, Ishak KG: Hepatic injury due to drugs and toxins. In Pathology of the Liver, 3rd ed. RNM MacSween, PP Anthony, PJ Scheuer, B Portmann, AD Burt (eds). Edinburgh, Churchill Livingstone, 1994
Farrell GC: Drug induced liver disease. Edinburgh, Churchill Livingstone, 1994
Lee WM: Drug induced hepatotoxicity. N Engl J Med 333:1118-1127, 1995
Scheuer PJ, Lefkowitch JH: Liver Biopsy interpretation. London, WB Saunders, 1994
Patel JA, Miller E, Hu J, et al: BRL 49653 (a thiazolidiniedione) improves glycemic control in NIDDM patients. Diabetes 46:150A, 1997 (abstract 0578)
Patel JA, Miller E, Patwardhan R, et al: Rosiglitazone (BRL 49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Proc 58th Annual Meeting of the ADA. Chicago, Illinois. June 13-16: A17, 1998 (abstract 0067)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Malik, A.H., Prasad, P., Saboorian, M. et al. CASE REPORT: Hepatic Injury Due to Troglitazone. Dig Dis Sci 45, 210–214 (2000). https://doi.org/10.1023/A:1005450519498
Issue Date:
DOI: https://doi.org/10.1023/A:1005450519498